Gilead and Vir unite to find a ‘functional cure’ for hepatitis B
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
As part of the clinical collaboration, the companies are expecting to launch a Phase II trial evaluating combination therapies for both treatment-experienced and treatment-naïve people living with HBV.
This study will evaluate a number of combinations of Gilead’s investigational TLR-8 agonist selgantolimod, Vir’s small interfering ribonucleic acid (siRNA) candidate VIR-2218 and a marketed PD-1 antagonist.
Study participants who have previously received treatment for HBV may also be given Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF).
Read more: http://www.pharmatimes.com/news/gilead_and_vir_unite_to_find_a_functional_cure_for_hepatitis_b_1361244
As part of the clinical collaboration, the companies are expecting to launch a Phase II trial evaluating combination therapies for both treatment-experienced and treatment-naïve people living with HBV.
This study will evaluate a number of combinations of Gilead’s investigational TLR-8 agonist selgantolimod, Vir’s small interfering ribonucleic acid (siRNA) candidate VIR-2218 and a marketed PD-1 antagonist.
Study participants who have previously received treatment for HBV may also be given Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF).
Read more: http://www.pharmatimes.com/news/gilead_and_vir_unite_to_find_a_functional_cure_for_hepatitis_b_1361244
